Navigation Links
2 Drugs Fail to Prevent Diabetes in the Overweight

Diovan, Starlix also had limited or no effect in shielding users from cardiovascular woes, study finds

SUNDAY, March 14 (HealthDay News) -- Hopes that two available drugs could help prevent diabetes and the problems it causes in overweight people with poor sugar metabolism have been dashed by a major international study.

The trial involved two drugs prescribed for other reasons -- Diovan (valsartan), a blood pressure medication; and Starlix (nateglinide), which is given to control existing type 2 diabetes.

The study was financed by Novartis, the drug company that markets both products.

The Starlix portion of the five-year trial, involving more than 9,300 overweight adults, found the drug had no benefit in reducing the incidence of newly diagnosed diabetes, cardiovascular death or events such as heart attack, stroke and heart failure.

The Diovan portion did find a modest effect -- 14 percent -- in preventing new diabetes cases. However, as was the case in the Starlix part of the trial, using Diovan led to no reduction in the cardiovascular conditions for which diabetes is a major risk factor.

Results of the trial were reported in two papers released early on March 13 by the New England Journal of Medicine, and slated for presentation Sunday at the American College of Cardiology's annual meeting, in Atlanta.

"It would be great if we had something that would prevent diabetes and cardiovascular disease at the same time," said Dr. Robert M. Califf, vice chancellor for clinical research at Duke University, and one of the leaders of the trial. "We didn't get that."

And despite the faintly positive results of the Diovan portion of the trial, "in neither case would we recommend such prophylactive [preventive] treatment in people who don't have diabetes but have abnormal glucose tolerance," Califf said.

So, lifestyle remains the key factor in preventing obesity and poor blood sugar control from turning into full-blown type 2 diabetes, he said.

"It looks like diet and exercise are the mainstays of prevention," he said. "If people could lose a few pounds more and exercise more, there would be a lot less diabetes."

It's an old message, but one that is difficult to get across, said Califf, who noted that more than 35 percent of the people in the trial did go on to develop diabetes in just five years. "We need to keep looking for better treatments, but lifestyle modification is the best thing we have going," he said.

The people in the trial, which was done at 806 centers across 40 countries, had diagnosed cardiovascular disease, known risk factors such as obesity and impaired ability to metabolize sugar.

They were divided into groups -- some receiving Diovan, some getting Starlix, and some taking a placebo. All entered a lifestyle modification program aimed at reducing weight and dietary fat intake and increasing physical activity.

Over five years, 36 percent of those taking Starlix developed diabetes, compared to 34 percent of those taking a placebo. Diabetes developed in about a third of those taking Diovan, compared to about 37 percent of those taking a placebo. The rates of cardiovascular problems and deaths were similar in all groups.

"We must continue to develop new therapies while encouraging people to exercise and pay attention to what they eat," Dr. John McMurray, professor of cardiology at the University of Glasgow in Scotland and a member of the trial's executive board, said in a Duke University news release. "Losing at little as 5 percent of body weight has been shown to make a dramatic difference in other studies."

Diabetes is a growing world-wide medical problem, McMurray and Califf noted. Some 150 million people now have the disease -- 90 percent have type 2 diabetes -- and the incidence is predicted to increase 50 percent by 2025.

There is an inexpensive drug available that has been shown to help prevent diabetes, added Dr. David M. Nathan, a professor of medicine at Harvard University and director of the Diabetes Research Center at Massachusetts General Hospital, who wrote an accompanying editorial in the New England Journal of Medicine. It is metformin, a leading drug for diabetes treatment that has been used for decades.

A study he led reported in 2002 that metformin reduced new diagnoses of diabetes by 58 percent over three years and by 34 percent over 10 years, Nathan wrote. But lifestyle changes, such as eating less and exercising more, are equally effective preventive measures, he said.

More information

Find out how you can help prevent diabetes at the American Diabetes Association.

SOURCES: Robert M. Califf, vice chancellor for clinical research, Duke University, Durham, N.C.; March 13, 2010, news release, Duke University; early online release, March 13, 2010, New England Journal of Medicine, and presentation, March 13, 2010, annual meeting, American College of Cardiology, Atlanta

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Long-Term Use of Osteoporosis Drugs Linked to Fractures
2. Find Safe, Affordable Prescription Alternatives at - New Site for Discount Prescription Drugs
3. UW Symposium: How Disease, Therapy, Drugs and Meditation Reshape the Brain
4. and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest
5. Quantity vs. quality: Long-term use of bone-building osteoporosis drugs
6. Physician calls for more rigorous standards for drugs up for FDA approval
7. The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years
8. Bleeding Alert Sounded for Stroke Drugs
9. Certain Bone Drugs May Lower Breast Cancer Risk
10. New Drugs, Approaches Offer Hope Against Prostate Cancer
11. Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs
Post Your Comments:
(Date:11/29/2015)... , ... November 29, 2015 , ... While conventional walkers ... or provide ready access to exercise weights. Fortunately, an inventor from Uniontown, Pa., has ... TOMMY WALKER to enhance the benefits of a standard walker to improve the user’s ...
(Date:11/28/2015)... ... November 28, 2015 , ... ... and teleradiology services, has added Chris Hafey and Claude Hooton to its board ... Radiological Society of North America (RSNA) 2015 Annual Meeting and continues to strategically ...
(Date:11/27/2015)... , ... November 28, 2015 , ... There is only ... outperform our billings from last year? , This question has not been an easy ... coming to the retirement age and the younger workforce don’t share the same discipline ...
(Date:11/27/2015)... Raleigh, NC (PRWEB) , ... November 27, 2015 , ... ... most effective ways to treat it. Surviving Mesothelioma has just posted the findings ... Researchers at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were ...
(Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... Germany , Nov. 29, 2015  At this ... attendees to experience the most complete mobile C-arm portfolio ... display is Ziehm Vision RFD 3D, the world,s only ... cm edge length per scan volume. In addition, Ziehm ... fully motorized mobile C-arm in four axes which is ...
(Date:11/29/2015)... 2015 CIVCO Medical Solutions will demonstrate ... Radiological Society of North America ... November 29 – December 4, 2015. The ... customers unrivaled versatility, enhanced user experience and deliver ... --> --> ...
(Date:11/27/2015)... Pays-Bas, November 27, 2015 ... traitement photodynamique au Bremachlorin contre le cancer avancé. ... consistant à combiner l,immunothérapie au traitement photodynamique au ... --> Une nouvelle approche consistant à ... le cancer avancé.    Clinical ...
Breaking Medicine Technology: